Restoring FDA’s Confidence In Labeling
This article was originally published in RPM Report
FDA’s decision to harmonize immediate-release and extended-release opioid labeling is an important step to address a political vulnerability for the agency and its new commissioner. But Commissioner Califf’s discussion of the role of FDA-approved labeling may be more important as an indicator of the overall drug approval climate – and a path forward in the thicket of First Amendment challenges to the agency’s marketing oversight.
Register for our free email digests: